The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options
Open accessAbstract
The emergence of immune checkpoint inhibitors targeting either the programmed death 1 (PD1) or cytotoxic T lymphocyte antigen 4 (CTLA4) axis represents a major therapeutic advance in treating lung cancer and other malignant diseases. These new treatments also convey risks for unpredictable, possibly severe, and potentially irreversible autoimmune toxic events that can have an effect on diverse organ systems. With combination immunotherapy regimens, rates of these events may exceed 50%. 1 To limit risk of immune-related adverse events, clinical trials of immune checkpoint inhibitors have routinely excluded patients with preexisting autoimmune disease, a population estimated to include 20 to 50 million individuals in the United States. 2 To determine the impact of this practice on patient eligibility for immunotherapy, we calculated the prevalence of autoimmune disease among patients diagnosed with lung cancer using a large, representative, population-based data set.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
Risks of myeloid malignancies in patients with autoimmune conditions
Anderson, L. A., Pfeiffer, R. M., Landgren, O., Gadalla, S., Berndt, S. I., & Engels, E. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604935 · Cited by 253
Cited by
Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., Azimi, R., Rizvi, H., Riess, J. W., Hellmann, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0305 · Cited by 341
Immune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339
“5% of lung cancer patients had a concurrent diagnosis of an autoimmune disease, and this suggests the urgency of exploring this population.(6)”
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Immune dysregulation in cancer patients developing immune-related adverse events
Khan, S., Khan, S. A., Luo, X., Fattah, F. J., Saltarski, J., Gloria-McCutchen, Y., Lu, R., Xie, Y., Li, Q., Wakeland, E., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0155-1 · Cited by 186
Self-citationA comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Metadata
- Authors
- Khan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-01
- Volume
- 2
- Issue
- 11
- Pages
- 1507
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2416974268
- Cited by
- 161
- References
- 3
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.